ArticleDrug design, development and therapy2026
An Evaluation of the Inhibitory Effect of Apatinib on Ilaprazole Metabolism: in vitro, in vivo and in silico Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ilaprazole is a novel proton pump inhibitor (PPI) approved orally in China and Korea for the treatment of gastric ulcers, duodenal ulcers (DU) and erosive esophagitis. It is mainly metabolized to ilaprazole sulfone by CYP3A4. Methods: The quantitative determination method of ilaprazole and its metabolite ilaprazole sulfone was optimized and fully validated by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). In addition, the effect of apatinib on ilaprazole and its metabolite ilaprazole sulfone was evaluated by in vitro and in vivo experiments using rat liver microsomes (RLM), human liver microsomes (HLM), molecular docking and Sprague-Dawley (SD) rats. Results: The results of bioanalytical methodology showed that ilaprazole and ilaprazole sulfone had good linear relationship in plasma samples, and their selectivity, accuracy, precision, stability, matrix effect, recovery, carry-over, dilution integrity and re-injection reproducibility all met the needs of quantitative analysis of samples. In vitro, apatinib inhibited the metabolism of ilaprazole with half-maximum inhibitory concentration (IC Conclusion: In vitro systems and SD rats, apatinib exhibited an inhibitory effect on the metabolism of ilaprazole. In addition, molecular docking provided structural context for the observed interaction. However, whether the same phenomenon exists in humans remains to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.